In the latest trading session, 0.39 million Viking Therapeutics Inc (NASDAQ:VKTX) shares changed hands as the company’s beta touched 1.00. With the company’s most recent per share price at $62.72 changing hands around $1.09 or 1.77% at last look, the market valuation stands at $6.95B. VKTX’s current price is a discount, trading about -58.5% off its 52-week high of $99.41. The share price had its 52-week low at $8.28, which suggests the last value was 86.8% up since then. When we look at Viking Therapeutics Inc’s average trading volume, we note the 10-day average is 3.32 million shares, with the 3-month average coming to 3.76 million.
Analysts gave the Viking Therapeutics Inc (VKTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended VKTX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Viking Therapeutics Inc’s EPS for the current quarter is expected to be -0.25.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Viking Therapeutics Inc (NASDAQ:VKTX) trade information
Instantly VKTX is in green as seen in intraday trades today. With action -3.52%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 237.02%, with the 5-day performance at -3.52% in the red. However, in the 30-day time frame, Viking Therapeutics Inc (NASDAQ:VKTX) is 0.11% up. Looking at the short shares, we see there were 15.91 million shares sold at short interest cover period of 4.79 days.
The consensus price target for the stock as assigned by Wall Street analysts is 110.5, meaning bulls need an upside of 43.24% from its recent market value. According to analyst projections, VKTX’s forecast low is 15 with 138 as the target high. To hit the forecast high, the stock’s price needs a -120.03% plunge from its current level, while the stock would need to tank 76.08% for it to hit the projected low.
Viking Therapeutics Inc (VKTX) estimates and forecasts
Data shows that the Viking Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -21.11% over the past 6 months, a -9.89% in annual growth rate that is considerably lower than the industry average of 17.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -18.89%. The 2024 estimates are for Viking Therapeutics Inc earnings to decrease by -8.42%, but the outlook for the next 5-year period is at 40.00% per year.
VKTX Dividends
Viking Therapeutics Inc is expected to release its next quarterly earnings report on 2024-Oct-23.
Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.03% of Viking Therapeutics Inc shares while 75.18% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 80.00%. There are 75.18% institutions holding the Viking Therapeutics Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 15.9876% of the shares, roughly 16.54 million VKTX shares worth $876.8 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.7599% or 10.1 million shares worth $535.26 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jul 31, 2024 were Fidelity Growth Company Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. With 3.74 shares estimated at $234.63 million under it, the former controlled 3.37% of total outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held about 3.29% of the shares, roughly 3.65 shares worth around $229.24 million.
